PRESS RELEASE

Q4 2025 — Press release

Q4 2025PDF · 16 pages462 KB
- 1 -
News Release
____________________________________________________________________________
Merck & Co., Inc., Rahway, N.J., USA Announces Fourth-Quarter and Full-Year
2025 Financial Results; Highlights Progress Advancing Broad, Diverse Pipeline
Reports Strength in Oncology and Animal Health, Plus Increasing Contributions From
WINREVAIR and CAPVAXIVE
- 	Fourth-Quarter Worldwide Sales Were $16.4 Billion (5% Growth; 4% Growth ex-FX)
- 	Fourth-Quarter GAAP EPS Was $1.19; Non-GAAP EPS Was $2.04; GAAP and Non-
GAAP EPS Include a Charge of $0.05 per Share for the Acquisition of MK-8690 Sole
Global Rights
- 	Full-Year Worldwide Sales Were $65.0 Billion (1% Growth; 2% Growth ex-FX)
o 	KEYTRUDA/KEYTRUDA QLEX Sales Were $31.7 Billion (7% Growth Both
Nominally and ex-FX); Includes KEYTRUDA QLEX Sales of $40 Million
o 	WINREVAIR Sales Were $1.4 Billion
o 	CAPVAXIVE Sales Were $759 Million
o 	GARDASIL/GARDASIL 9 Sales Were $5.2 Billion (39% Decline Both Nominally
and ex-FX)
o 	Animal Health Sales Were $6.4 Billion (8% Growth; 9% Growth ex-FX)
- 	Full-Year 2025 GAAP EPS Was $7.28; Non-GAAP EPS Was $8.98; GAAP and Non-
GAAP EPS Include Charges of $0.20 per Share Related to Certain Business
Development Transactions
- 	Announced Positive Late-Stage Trial Results From 18 Phase 3 Trials in 2025
- 	Augmented Pipeline and Portfolio Through Acquisitions of Verona Pharma and Cidara
Therapeutics and License Agreement With Hengrui Pharma
- 	In the Fourth Quarter
o 	Received FDA Commissioner’s National Priority Vouchers for Enlicitide and
Sacituzumab Tirumotecan (Sac-TMT), Providing an Opportunity To Expedite
Potential FDA Review Timelines for These Phase 3 Candidates
o 	Presented Positive Results From Phase 3 CORALreef Lipids and HeFH Trials
Demonstrating Enlicitide Significantly Reduced LDL-C in Adults
o 	Reached Agreement With U.S. Government To Expand Access to Medicines and
Lower Costs for Americans
- 	Full-Year 2026 Financial Outlook
- 	Anticipates Worldwide Sales To Be Between $65.5 Billion and $67.0 Billion
- 	Expects Non-GAAP EPS To Be Between $5.00 and $5.15; Outlook Reflects a
One-Time Charge of Approximately $3.65 per Share for the Acquisition of Cidara

-- 1 of 16 --

- 2 -
RAHWAY, N.J., Feb. 3, 2026 – Merck & Co., Inc., Rahway, N.J., USA (NYSE: MRK), known as
MSD outside the United States and Canada, today announced financial results for the fourth
quarter and full year of 2025.
"In 2025, we continued to advance leading-edge science to deliver transformative
medicines and vaccines that are improving health outcomes for patients around the world,” said
Robert M. Davis, chairman and chief executive officer. "Our business benefited from demand for
our innovative portfolio, including for KEYTRUDA, increasing contributions from new launches in
cardiometabolic and respiratory as well as vaccines, and strong performance of Animal Health.
The transformation of our portfolio, bolstered by the acquisitions of Verona Pharma and Cidara
Therapeutics, is well underway, and momentum is building as we continue to execute on our
strategy. Our progress positions us to continue delivering on our purpose for patients and
creating durable value for shareholders.”
Financial Summary
$ in millions,
except EPS
amounts
Fourth Quarter 	Year Ended
2025 	2024 	Change
Change Ex-
Exchange
Dec. 31,
2025
Dec. 31,
2024 	Change
Change Ex-
Exchange
Sales 	$16,400 	$15,624 	5% 	4% 	$65,011 	$64,168 	1% 	2%
GAAP net
income1 	2,963 	3,743 	-21% 	-20% 	18,254 	17,117 	7% 	9%
Non-GAAP net
income that
excludes
certain
items1,2* 	5,088 	4,372 	16% 	17% 	22,513 	19,444 	16% 	18%
GAAP EPS 	1.19 	1.48 	-20% 	-18% 	7.28 	6.74 	8% 	10%
Non-GAAP
EPS that
excludes
certain items2* 	2.04 	1.72 	19% 	19% 	8.98 	7.65 	17% 	19%
*Refer to table on page 9.
Generally Accepted Accounting Principles (GAAP) earnings per share (EPS) assuming
dilution was $1.19 for the fourth quarter and $7.28 for the full year of 2025. Non-GAAP EPS was
$2.04 for the fourth quarter and $8.98 for the full year of 2025. GAAP and non-GAAP EPS in the
fourth quarter of 2025 include a charge of $0.05 per share related to an agreement with Dr. Falk
Pharma GmbH (Falk) pursuant to which the Company secured the sole global rights to MK-
8690. GAAP and non-GAAP EPS in the fourth quarter of 2024 include a charge of $0.23 per
share related to the execution of licensing agreements with LaNova Medicines Ltd. (acquired by
Sino Pharmaceutical Limited) and Hansoh Pharma. GAAP and non-GAAP EPS for the full years
1 Net income attributable to the Company.
2 The Company is providing certain 2025 and 2024 non-GAAP information that excludes certain items because of the nature of
these items and the impact they have on the analysis of underlying business performance and trends. Management believes that
providing this information enhances investors’ understanding of the Company’s results because management uses non-GAAP
results to assess performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to
measure the performance of the Company along with other metrics. In addition, annual employee compensation, including senior
management’s compensation, is derived in part using a non-GAAP pretax income metric. This information should be considered in
addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. For a description of the non-
GAAP adjustments, see Table 2a attached to this release.

-- 2 of 16 --

- 3 -
of 2025 and 2024 include charges of $0.20 and $1.28 per share, respectively, related to certain
licensing agreements and asset acquisitions.
Non-GAAP EPS excludes acquisition- and divestiture-related costs, costs related to
restructuring programs, and income and losses from investments in equity securities. Non-
GAAP EPS in 2025 also excludes a net tax benefit, which reflects a net benefit related to
favorable audit reserve adjustments. Non-GAAP EPS in the fourth quarter and full year of 2024
also exclude a benefit due to a reduction in reserves for unrecognized income tax benefits
resulting from the expiration of the statute of limitations for assessments related to certain
federal tax return years.
Fourth-Quarter Sales Performance
The following table reflects sales of the Company’s top products and significant
performance drivers.
Fourth Quarter
$ in millions 	2025 	2024 	Change
Change Ex-
Exchange 	Commentary
Total Sales 	$16,400 	$15,624 	5% 	4%
Pharmaceutical 	14,843 	14,042 	6% 	4%
Increase primarily driven by growth in
oncology as well as cardiometabolic and
respiratory, partially offset by a decline in
vaccines.
KEYTRUDA/
KEYTRUDA QLEX 	8,372 	7,836 	7% 	5%
Growth driven by strong global uptake in
earlier-stage indications, including triple-
negative breast cancer (TNBC), non-small
cell lung cancer (NSCLC), renal cell
carcinoma, cervical and head and neck
cancers, as well as continued global
demand in metastatic indications,
including urothelial, gastric and
endometrial cancers. Sales growth was
partially offset by timing of purchases in
the U.S. Sales of KEYTRUDA QLEX were
$35 million.
GARDASIL/GARDASIL 9 	1,031 	1,550 	-34% 	-35%
Decline primarily due to lower demand in
China, as well as lower sales in Japan
following the national catch-up
immunization program, partially offset by
higher sales in the U.S. and timing in
certain international markets.
PROQUAD, M-M-R II and
VARIVAX 	619 	594 	4% 	3%
Increase primarily reflects higher sales of
PROQUAD, which largely resulted from
both the replenishment of doses borrowed
from the U.S. Centers for Disease Control
and Prevention Pediatric Vaccine
Stockpile and from higher demand in
Europe, partially offset by lower demand
for M-M-R II in certain international
markets and lower demand for VARIVAX
in the U.S.

-- 3 of 16 --

- 4 -
JANUVIA/JANUMET 	501 	487 	3% 	3%
Growth driven by higher net pricing in the
U.S., partially offset by lower demand in
China as well as in most other
international markets due to generic
competition.
BRIDION 	499 	449 	11% 	11%
Growth primarily due to higher demand
and net pricing in the U.S., partially offset
by lower demand in several international
markets due to ongoing generic
competition.
WINREVAIR 	467 	200 	133% 	133%
Growth primarily reflects continued uptake
in the U.S. and early launch uptake in
certain international markets, partially
offset by lower net pricing in the U.S.
largely due to Medicare Part D redesign.
Lynparza* 	389 	365 	7% 	4%
Growth primarily due to higher demand in
several international markets.
CAPVAXIVE 	279 	50 	N/M 	N/M
Growth largely due to continued uptake in
the U.S.
PREVYMIS 	275 	215 	28% 	26%
Increase primarily due to higher demand
in the U.S. as well as in most international
markets, reflecting in part the launch of
new indications.
Lenvima* 	272 	255 	7% 	6%
Increase due to higher sales in the U.S.,
primarily reflecting higher demand,
partially offset by lower pricing.
WELIREG 	220 	160 	37% 	37%
Growth primarily due to higher demand in
the U.S. and continued launch uptake in
several international markets, partially
offset by lower net pricing in the U.S.
OHTUVAYRE 	178 	- 	- 	-
Represents sales following the
Company's Oct. 7, 2025 acquisition of
Verona Pharma plc (Verona Pharma).
Animal Health 	1,505 	1,397 	8% 	6%
Growth primarily due to higher demand of
livestock products.
Livestock 	987 	889 	11% 	9%
Growth primarily driven by higher demand
across all species, as well as improved
supply and new product launches.
Companion Animal 	518 	508 	2% 	0%
Growth from new product launches was
partially offset by lower demand for other
products in portfolio, reflecting a reduction
in veterinary visits. Sales of BRAVECTO
line of products were $222 million and
$209 million in current and prior-year
quarters, respectively, which represents
an increase of 6%, or 5% excluding
impact of foreign exchange.
Other Revenues** 	52 	185 	-71% 	-15%
Decline primarily due to unfavorable
impact of revenue-hedging activities and
lower revenue from third-party
manufacturing arrangements.
*Alliance revenue for this product represents the Company’s share of profits, which are product sales net of cost of sales and
commercialization costs.
**Other revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues,
including revenue-hedging activities.
N/M - Not meaningful.

-- 4 of 16 --

- 5 -
Full-Year Sales Performance
The following table reflects sales of the Company’s top products and significant
performance drivers.
Year Ended
$ in millions 	Dec. 31, 2025 	Dec. 31, 2024 	Change
Change Ex-
Exchange
Total Sales 	$65,011 	$64,168 	1% 	2%
Pharmaceutical 	58,142 	57,400 	1% 	1%
KEYTRUDA/KEYTRUDA QLEX 	31,680 	29,482 	7% 	7%
GARDASIL/GARDASIL 9 	5,233 	8,583 	-39% 	-39%
JANUVIA/JANUMET 	2,544 	2,268 	12% 	13%
PROQUAD, M-M-R II and VARIVAX 	2,451 	2,485 	-1% 	-2%
BRIDION 	1,841 	1,764 	4% 	4%
Lynparza* 	1,450 	1,311 	11% 	10%
WINREVAIR 	1,443 	419 	N/M 	N/M
Lenvima* 	1,053 	1,010 	4% 	4%
PREVYMIS 	978 	785 	25% 	23%
VAXNEUVANCE 	825 	808 	2% 	1%
CAPVAXIVE 	759 	97 	N/M 	N/M
WELIREG 	716 	509 	41% 	41%
ROTATEQ 	673 	711 	-5% 	-5%
Reblozyl* 	525 	371 	41% 	41%
LAGEVRIO 	380 	964 	-61% 	-61%
Simponi** 	- 	543 	-100% 	-100%
Animal Health 	6,354 	5,877 	8% 	9%
Livestock 	3,896 	3,462 	13% 	14%
Companion Animal 	2,458 	2,415 	2% 	2%
Other Revenues*** 	515 	891 	-42% 	-6%
*Alliance revenue for Lynparza and Lenvima represent the Company’s share of profits, which are product sales net of cost of sales and
commercialization costs. Alliance revenue for Reblozyl represents royalties.
**Marketing rights in former territories of the Company reverted to Johnson & Johnson on Oct. 1, 2024.
***Other revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues,
including revenue-hedging activities.
N/M - Not meaningful.
In addition, Koselugo alliance revenue was $436 million for the full year of 2025
compared with $170 million for the full year of 2024. The increase was due to an amendment to
the collaboration agreement with AstraZeneca in 2025, which discontinued the provisions
whereby the Company shared revenue and costs with AstraZeneca, and revised the payment
structure, resulting in the Company’s recognition of a $150 million upfront payment and $175
million of regulatory milestones.
Full-year 2025 Pharmaceutical sales were $58.1 billion, representing growth of 1% both
nominally and excluding the impact of foreign exchange. Sales growth was primarily driven by
higher sales in oncology, particularly KEYTRUDA and WELIREG, as well as increased alliance
revenue from Koselugo (resulting from the amendment to the collaboration agreement noted
above), Reblozyl and Lynparza. Also contributing to sales growth were higher sales in the
cardiometabolic and respiratory franchise largely attributable to the ongoing launch of
WINREVAIR, as well as the inclusion of OHTUVAYRE sales resulting from the acquisition of
Verona Pharma, which closed on Oct. 7, 2025. Growth in the diabetes franchise, largely
attributable to higher net pricing of JANUVIA in the U.S., also contributed to sales growth. Sales

-- 5 of 16 --

- 6 -
growth in 2025 was partially offset by lower sales in the vaccines franchise reflecting lower sales
of GARDASIL/GARDASIL 9, which were offset in part by the ongoing launch of CAPVAXIVE
and the U.S. launch of ENFLONSIA. Lower sales in the immunology franchise (due to the return
of the marketing rights for Simponi and Remicade in former Company territories to Johnson &
Johnson on Oct. 1, 2024) and lower sales in the virology franchise (largely attributable to
LAGEVRIO) also offset Pharmaceutical sales growth in 2025.
Full-year 2025 Animal Health sales were $6.4 billion, representing growth of 8%, or 9%
excluding the impact of foreign exchange. Sales growth was primarily driven by the performance
of Livestock products across all species and new product launches in Companion Animal. Sales
of the BRAVECTO line of products were $1.1 billion in 2025, representing growth of 1% both
nominally and excluding the impact of foreign exchange.
Fourth-Quarter and Full-Year Expense and Related Information
The table below presents selected expense information.
$ in millions 	GAAP
Acquisition-
and
Divestiture-
Related
Costs3
Restructuring
Costs
(Income)
Loss From
Investments
in Equity
Securities
Non-
GAAP2
Fourth Quarter 2025
Cost of sales 	$5,551 	$1,054 	$1,173 	$- 	$3,324
Selling, general and administrative 	2,898 	48 	2 	- 	2,848
Research and development 	3,886 	5 	(111) 	- 	3,992
Restructuring costs 	213 	- 	213 	- 	-
Other (income) expense, net 	432 	- 	- 	206 	226
Fourth Quarter 2024
Cost of sales 	$3,828 	$701 	$121 	$- 	$3,006
Selling, general and administrative 	2,864 	29 	16 	- 	2,819
Research and development 	4,585 	12 	(1) 	- 	4,574
Restructuring costs 	51 	- 	51 	- 	-
Other (income) expense, net 	126 	(31) 	- 	152 	5
3 Reflects expenses related to business combinations, including the amortization of intangible assets, intangible asset impairment
charges, and expense or income related to changes in the estimated fair value measurement of liabilities for contingent
consideration. Also includes integration, transaction and certain other costs associated with acquisitions and divestitures, as well
as amortization of intangible assets related to collaborations, licensing arrangements and asset acquisitions, and recognition of fair
value step-up to inventories for asset acquisitions.

-- 6 of 16 --

- 7 -
$ in millions 	GAAP
Acquisition-
and
Divestiture-
Related
Costs3
Restructuring
Costs
(Income)
Loss From
Investments
in Equity
Securities
Non-
GAAP2
Year Ended Dec. 31, 2025
Cost of sales 	$16,382 	$2,871 	$1,484 	$- 	$12,027
Selling, general and administrative 	10,733 	120 	3 	- 	10,610
Research and development 	15,789 	19 	175 	- 	15,595
Restructuring costs 	889 	- 	889 	- 	-
Other (income) expense, net 	151 	(3) 	- 	(306) 	460
Year Ended Dec. 31, 2024
Cost of sales 	$15,193 	$2,409 	$495 	$- 	$12,289
Selling, general and administrative 	10,816 	117 	83 	- 	10,616
Research and development 	17,938 	72 	1 	- 	17,865
Restructuring costs 	309 	- 	309 	- 	-
Other (income) expense, net 	(24) 	(79) 	- 	45 	10
GAAP Expense, EPS and Related Information
Gross margin was 66.2% for the fourth quarter of 2025 compared with 75.5% for the
fourth quarter of 2024. Gross margin was 74.8% for the full year of 2025 compared with 76.3%
for the full year of 2024. The gross margin decline in both periods was primarily due to the
unfavorable impacts of higher restructuring costs (primarily related to the accelerated
depreciation of manufacturing lines at two sites under the 2025 Restructuring Program),
inventory write-offs and amortization of intangible assets, as well as the recognition of inventory
fair value step-up related to the Verona Pharma acquisition, partially offset by the favorable
impact of product mix.
Selling, general and administrative (SG&A) expenses were $2.9 billion in the fourth
quarter of 2025, an increase of 1% compared with the fourth quarter of 2024. The increase was
primarily due to higher administrative costs, partially offset by lower promotional costs. Full-year
2025 SG&A expenses were $10.7 billion, a decrease of 1% compared with the full year of 2024.
The decrease was primarily due to lower restructuring and promotional costs, partially offset by
increased administrative costs.
Research and development (R&D) expenses were $3.9 billion in the fourth quarter of
2025, a decrease of 15% compared with the fourth quarter of 2024. The decrease was primarily
due to lower charges for business development activity and a reduction to estimated contractual
termination costs associated with restructuring actions, partially offset by higher clinical
development costs. R&D expenses were $15.8 billion for the full year of 2025, a decrease of
12% compared with the full year of 2024. The decrease was primarily due to lower charges for
business development activity, partially offset by higher clinical development spending and
higher restructuring costs.
Other (income) expense, net, was $432 million of expense in the fourth quarter of 2025
compared with $126 million of expense in the fourth quarter of 2024 primarily due to higher net
interest expense, higher foreign exchange losses and increased net losses from investments in
equity securities. Other (income) expense, net, was $151 million of expense in the full year of

-- 7 of 16 --

- 8 -
2025 compared with $24 million of income in the full year of 2024. The unfavorable year-over-
year change primarily reflects $170 million of income in 2024 related to the expansion of an
existing development and commercialization agreement with Daiichi Sankyo, as well as higher
net interest expense and higher foreign exchange losses in 2025, partially offset by higher net
income from investments in equity securities in 2025.
The effective tax rate was 13.4% for the fourth quarter of 2025 and 13.3% for the full
year of 2025.
GAAP EPS was $1.19 for the fourth quarter of 2025 compared with $1.48 for the fourth
quarter of 2024. The decrease was primarily driven by higher restructuring costs and
amortization of intangible assets, partially offset by favorability from lower charges for business
development transactions, as well as operational strength in the business driven in part by the
benefits of the previously announced multiyear optimization initiative. GAAP EPS was $7.28 for
the full year of 2025 compared with $6.74 for the full year of 2024. The increase was primarily
driven by favorability from lower charges for business development transactions and operational
strength in the business, partially offset by higher restructuring costs and amortization of
intangible assets.
Non-GAAP Expense, EPS and Related Information
Non-GAAP gross margin was 79.7% for the fourth quarter of 2025 compared with 80.8%
for the fourth quarter of 2024. The decrease was primarily due to higher inventory write-offs,
partially offset by the favorable impact of product mix. Non-GAAP gross margin was 81.5% for
the full year of 2025 compared with 80.8% for the full year of 2024. The increase was primarily
due to the favorable impact of product mix, partially offset by higher inventory write-offs.
Non-GAAP SG&A expenses were $2.8 billion in the fourth quarter of 2025, an increase
of 1% compared with the fourth quarter of 2024. The increase was primarily due to higher
administrative costs, partially offset by lower promotional costs. Non-GAAP SG&A expenses
were $10.6 billion for the full year of 2025, flat compared with the full year of 2024 as lower
promotional costs were largely offset by higher administrative costs.
Non-GAAP R&D expenses were $4.0 billion in the fourth quarter of 2025, a decrease of
13% compared with the fourth quarter of 2024. Non-GAAP R&D expenses were $15.6 billion for
the full year of 2025, a decrease of 13% compared with the full year of 2024. The decrease in
both periods was primarily due to lower charges for business development activity, partially
offset by higher clinical development costs.
Non-GAAP other (income) expense, net, was $226 million of expense in the fourth
quarter of 2025 compared with $5 million of expense in the fourth quarter of 2024 primarily due
to higher net interest expense and higher foreign exchange losses. Non-GAAP other (income)
expense, net, was $460 million of expense in the full year of 2025 compared with $10 million of
expense in the full year of 2024. The unfavorable year-over-year change primarily reflects $170
million of income in 2024 related to the expansion of an existing development and

-- 8 of 16 --

- 9 -
commercialization agreement with Daiichi Sankyo, as well as higher net interest expense and
higher foreign exchange losses in 2025.
The non-GAAP effective tax rate was 15.4% for the fourth quarter of 2025 and 14.4% for
the full year of 2025.
Non-GAAP EPS was $2.04 for the fourth quarter of 2025 compared with $1.72 for the
fourth quarter of 2024. Non-GAAP EPS was $8.98 for the full year of 2025 compared with $7.65
for the full year of 2024. The increase in both periods was primarily driven by favorability from
lower charges for business development transactions, as well as operational strength in the
business driven in part by the benefits of the previously announced multiyear optimization
initiative.
A reconciliation of GAAP to non-GAAP net income and EPS is provided in the table that
follows.
4 Includes the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the
non-GAAP adjustments for all periods presented. Amount in the full year of 2025 also includes a $60 million net benefit, which
reflects a net benefit related to favorable audit reserve adjustments. Amounts in the fourth quarter and full year of 2024 also include
a $260 million benefit and a $519 million benefit, respectively, due to reductions in reserves for unrecognized income tax benefits
resulting from the expiration of the statute of limitations for assessments related to certain federal tax return years. The benefit
recognized in the fourth quarter of 2024 relates to the 2020 federal tax return year and the benefit for the full year of 2024 relates to
both the 2020 and 2019 federal tax return years.
Fourth Quarter 	Year Ended
$ in millions, except EPS amounts 	2025 	2024
Dec. 31,
2025
Dec. 31,
2024
EPS
GAAP EPS 	$1.19 	$1.48 	$7.28 	$6.74
Difference 	0.85 	0.24 	1.70 	0.91
Non-GAAP EPS that excludes items listed below2 	$2.04 	$1.72 	$8.98 	$7.65
Net Income
GAAP net income1 	$2,963 	$3,743 	$18,254 	$17,117
Difference 	2,125 	629 	4,259 	2,327
Non-GAAP net income that excludes items listed below1,2 	$5,088 	$4,372 	$22,513 	$19,444
Excluded Items:
Acquisition- and divestiture-related costs3 	$1,107 	$711 	$3,007 	$2,519
Restructuring costs 	1,277 	187 	2,551 	888
Loss (income) from investments in equity securities 	206 	152 	(306) 	45
Decrease to net income before taxes 	2,590 	1,050 	5,252 	3,452
Estimated income tax (benefit) expense4 	(465) 	(421) 	(993) 	(1,125)
Decrease to net income 	$2,125 	$629 	$4,259 	$2,327

-- 9 of 16 --

- 10 -
Pipeline and Portfolio Highlights
In 2025, the Company announced positive late-stage trial results from 18 Phase 3 trials
and began enrolling patients in 21 new Phase 3 studies evaluating multiple indications and
therapeutic areas, with approximately 80 Phase 3 studies currently underway.
Throughout the fourth quarter, the Company made important progress to advance its
broad, diverse pipeline, meeting significant regulatory and clinical milestones.
• 	Oncology:
o 	U.S. Food and Drug Administration (FDA) approved KEYTRUDA and
KEYTRUDA QLEX, each in combination with Padcev, for the perioperative
treatment of adult patients with muscle-invasive bladder cancer (MIBC) who are
ineligible for cisplatin-based chemotherapy based on Phase 3 KEYNOTE-905
trial.
§ 	Approvals represent the first PD-1 inhibitor plus antibody-drug conjugate
(ADC) regimens for this patient population.
o 	FDA awarded a priority review voucher under the Commissioner’s National
Priority Voucher (CNPV) pilot program for sac-TMT, an investigational anti-
TROP2 ADC being developed in collaboration with Kelun-Biotech.
o 	European Commission (EC) approved the subcutaneous route of administration
and new pharmaceutical formulation of KEYTRUDA for use across all
KEYTRUDA indications for adult patients in Europe.
o 	FDA accepted two supplemental Biologics License Applications (sBLAs) for
KEYTRUDA and KEYTRUDA QLEX, each with Trodelvy, for the first-line
treatment of certain patients with PD-L1+ inoperable (unresectable) locally
advanced or metastatic TNBC based on Phase 3 KEYNOTE-D19/ASCENT-04
trial.
§ 	FDA set Prescription Drug User Fee Act (PDUFA) dates in the second
half of 2026 for these applications.
o 	Announced positive topline results from Phase 3 KEYNOTE-B15 trial in patients
with MIBC who are eligible for cisplatin-based chemotherapy showing
KEYTRUDA plus Padcev significantly improved event-free survival (EFS), overall
survival (OS) and pathologic complete response (pCR) rates versus neoadjuvant
chemotherapy and surgery when given before and after surgery.
o 	In collaboration with Moderna, Inc. (Moderna), announced median five-year
follow-up data from Phase 2b KEYNOTE-942/mRNA-4157-P201 study for
intismeran autogene, an investigational mRNA-based individualized neoantigen
therapy, in combination with KEYTRUDA in patients with high-risk melanoma
(stage III/IV) following complete resection.
• 	Infectious Diseases:
o 	Announced positive topline results from the Phase 3 trial of the investigational,
once-daily, oral, two-drug, single-tablet regimen of doravirine/islatravir (DOR/ISL)

-- 10 of 16 --

- 11 -
for the treatment of adults with HIV-1 infection who had not previously received
antiretroviral treatment (treatment-naïve).
• 	Cardiometabolic and Respiratory:
o 	Presented new data at the American Heart Association Scientific Sessions 2025,
including results from the Phase 3 CORALreef Lipids and heterozygous familial
hypercholesterolemia (HeFH) trials, demonstrating that enlicitide decanoate, an
investigational, oral proprotein convertase subtilisin/kexin type 9 (PCSK9)
inhibitor being evaluated for the treatment of adults with hypercholesterolemia,
significantly reduced low-density lipoprotein cholesterol (LDL-C) with a safety
profile comparable to placebo.
§ 	FDA awarded a priority review voucher under the CNPV pilot program for
enlicitide decanoate.
o 	In January 2026, EC approved an expanded indication for WINREVAIR, in
combination with other pulmonary arterial hypertension (PAH) therapies, for the
treatment of PAH (Group 1 pulmonary hypertension) in adult patients with World
Health Organization (WHO) Functional Class II, III and IV based on Phase 3
ZENITH trial.
o 	In February 2026, FDA accepted a new sBLA for WINREVAIR seeking approval
to update the U.S. product label based on Phase 3 HYPERION trial.
§ 	FDA set PDUFA date of September 21, 2026.
o 	Announced that Phase 2, proof-of-concept CADENCE study evaluating
WINREVAIR in adults for the treatment of combined post- and precapillary
pulmonary hypertension (CpcPH) due to heart failure with preserved ejection
fraction (HFpEF) met its primary endpoint.
• 	Business Development:
o 	In 2026, completed acquisition of Cidara Therapeutics, Inc. (Cidara) for a total
transaction value of approximately $9.2 billion.
§ 	Added MK-1406 (formerly CD388), an investigational long-acting, strain-
agnostic antiviral agent designed to prevent influenza infection in
individuals at higher risk of complications, to the Company’s portfolio.
§ 	MK-1406 is currently being evaluated in the Phase 3 ANCHOR study.
o 	Entered into strategic financing agreement with Blackstone Life Sciences to
partially fund the development of sac-TMT in 2026.
o 	Entered into an agreement with Falk for certain development and
commercialization rights to MK-8690, an investigational anti-CD30 ligand
monoclonal antibody.

-- 11 of 16 --

- 12 -
Notable recent news releases on the Company’s pipeline and portfolio are provided in
the table that follows. Visit the News Releases section of the Company’s website to read the
releases.*
Oncology
FDA Approved KEYTRUDA and KEYTRUDA QLEX, Each With Padcev, as Perioperative
Treatment for Adults With Cisplatin-Ineligible MIBC; Based on Results From Phase 3
KEYNOTE-905 Trial
EC Approved Subcutaneous Administration of KEYTRUDA for All Adult Indications
Approved in EU; Based on Results From Phase 3 3475A-D77 Trial
KEYTRUDA Plus Padcev Significantly Improved EFS, OS and pCR Rates for Cisplatin-
Eligible Patients With MIBC When Given Before and After Surgery; Based on Results
From Phase 3 KEYNOTE-B15 Trial
The Company and Moderna Announced 5-Year Data for Intismeran Autogene in
Combination With KEYTRUDA Demonstrated Sustained Improvement in the Primary
Endpoint of Recurrence-Free Survival in Patients With High-Risk Stage III/IV Melanoma
Following Complete Resection; Based on Follow-up Analysis From Phase 2b KEYNOTE-
942/mRNA-4157-P201 Trial
The Company Initiated Phase 3 KANDLELIT-007 Trial Evaluating Calderasib (MK-1084),
an Investigational Oral KRAS G12C Inhibitor, in Combination With KEYTRUDA QLEX in
Certain Patients With Advanced NSCLC
The Company Presented Data at the American Society of Hematology Annual Meeting
2025 That Showcased Continued Advancements in Hematology Pipeline and Novel
Therapeutic Approaches
Vaccines and
Infectious Diseases
The Company Announced Positive Topline Results From Pivotal Phase 3 Trial Evaluating
Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of DOR/ISL in
Treatment-Naïve Adults With HIV-1 Infection
Cardiometabolic and
Respiratory
Enlicitide Decanoate Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial
Enlicitide Decanoate Significantly Reduced LDL-C in Adults With HeFH in Phase 3
CORALreef HeFH Trial
WINREVAIR Met Primary Endpoint in Phase 2, Proof-Of-Concept CADENCE Study in
Adults With CpcPH Due to HFpEF
Neuroscience The Company Showcased Data for Alzheimer’s Disease Candidates MK-2214 and MK-
1167 at Clinical Trials on Alzheimer’s Disease 2025
Animal Health FDA Conditionally Approved EXZOLT CATTLE-CA1 for Prevention and Treatment of New
World Screwworm (Cochliomyia Hominivorax) Larvae (Myiasis)
*References to the Company’s name in the above news release titles have been modified for the purpose of this announcement.
U.S. Government Agreement
The Company reached an agreement with the U.S. government that is intended to lower
medicine costs for Americans. This agreement enables the Company to continue its long-
standing commitment to advancing breakthrough scientific discoveries for patients and helps
ensure Americans can access the medicines they need at lower costs. The voluntary agreement
addresses all four components of the President’s July letter.
Under the agreement, among other things, the Company plans to provide key products
through a direct-to-patient program at affordable prices for eligible patients in the U.S. In
addition, the Company reached an understanding with the U.S. Department of Commerce to
delay Section 232 tariffs for three years, enabling the Company to make investments in the U.S.
to reshore manufacturing for American patients. The Company has committed more than $70
billion in capital and R&D spending to strengthen U.S. production and innovation.

-- 12 of 16 --

- 13 -
Full-Year 2026 Financial Outlook
The following table summarizes the Company’s full-year financial outlook.
Full Year 2026
Sales* 	$65.5 billion to $67.0 billion
Non-GAAP Gross margin2 	Approximately 82%
Non-GAAP Operating expenses2** 	$35.9 billion to $36.9 billion
Non-GAAP Other (income) expense, net2 	Approximately $1.3 billion expense
Non-GAAP Effective tax rate2 	23.5% to 24.5%
Non-GAAP EPS2*** 	$5.00 to $5.15
Share count (assuming dilution) 	Approximately 2.48 billion
*The Company does not have any non-GAAP adjustments to sales.
**Includes a one-time charge of approximately $9.0 billion associated with the acquisition of Cidara. Outlook does not assume any
additional significant potential business development transactions.
***Includes a one-time charge of approximately $3.65 per share associated with the acquisition of Cidara.
The Company has not provided a reconciliation of forward-looking non-GAAP gross
margin, non-GAAP operating expenses, non-GAAP other (income) expense, net, non-GAAP
effective tax rate and non-GAAP EPS to the most directly comparable GAAP measures, given it
cannot predict with reasonable certainty the amounts necessary for such a reconciliation,
including intangible asset impairment charges, legal settlements, and income and losses from
investments in equity securities either owned directly or through ownership interests in
investment funds, without unreasonable effort. These items are inherently difficult to forecast
and could have a significant impact on the Company’s future GAAP results.
The Company anticipates full-year 2026 sales to be between $65.5 billion and $67.0
billion, including a positive impact from foreign exchange of approximately 1% at mid-January
2026 exchange rates.
The Company’s full-year non-GAAP effective income tax rate is expected to be between
23.5% and 24.5% including the impact of the non-tax deductible one-time charge for the
acquisition of Cidara.
The Company expects full-year 2026 non-GAAP EPS to be between $5.00 and $5.15,
including a positive impact from foreign exchange of approximately $0.10 per share at mid-
January 2026 exchange rates. This range includes a one-time charge of approximately $9.0
billion, or approximately $3.65 per share, as well as approximately $0.30 per share of related
financing and operational costs, related to the acquisition of Cidara. In 2025, non-GAAP EPS of
$8.98 was negatively impacted by one-time charges of $0.20 per share related to certain
business development transactions.
Consistent with past practice, the financial outlook does not assume additional
significant potential business development transactions.
Non-GAAP EPS excludes acquisition- and divestiture-related costs, costs related to
restructuring programs, as well as income and losses from investments in equity securities.

-- 13 of 16 --

- 14 -
Earnings Conference Call
Investors, journalists and the general public may access a live audio webcast of the call
on Tuesday, Feb. 3, at 9 a.m. ET via this weblink. A replay of the webcast, along with the sales
and earnings news release, supplemental financial disclosures and slides highlighting the
results, will be available on the Company’s website.
All participants may join the call by dialing (800) 369-3351 (U.S. and Canada Toll-Free)
or (517) 308-9448 and using the access code 9818590.
About Our Company
At Merck & Co., Inc., Rahway, N.J., USA, known as MSD outside of the United States
and Canada, we are unified around our purpose: We use the power of leading-edge science to
save and improve lives around the world. For more than 130 years, we have brought hope to
humanity through the development of important medicines and vaccines. We aspire to be the
premier research-intensive biopharmaceutical company in the world – and today, we are at the
forefront of research to deliver innovative health solutions that advance the prevention and
treatment of diseases in people and animals. We foster a diverse and inclusive global workforce
and operate responsibly every day to enable a safe, sustainable and healthy future for all
people and communities.
Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA
This news release of Merck & Co., Inc., Rahway, N.J., USA (the “Company”) includes
“forward-looking statements” within the meaning of the safe harbor provisions of the U.S.
Private Securities Litigation Reform Act of 1995. These statements are based upon the current
beliefs and expectations of the Company’s management and are subject to significant risks and
uncertainties. There can be no guarantees with respect to pipeline candidates that the
candidates will receive the necessary regulatory approvals or that they will prove to be
commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties
materialize, actual results may differ materially from those set forth in the forward-looking
statements.
Risks and uncertainties include but are not limited to, general industry conditions and
competition; general economic factors, including interest rate and currency exchange rate
fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the
United States and internationally; global trends toward health care cost containment;
technological advances, new products and patents attained by competitors; challenges inherent
in new product development, including obtaining regulatory approval; the Company’s ability to
accurately predict future market conditions; manufacturing difficulties or delays; financial
instability of international economies and sovereign risk; dependence on the effectiveness of the
Company’s patents and other protections for innovative products; and the exposure to litigation,
including patent litigation, and/or regulatory actions.

-- 14 of 16 --

- 15 -
The Company undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events or otherwise. Additional factors
that could cause results to differ materially from those described in the forward-looking
statements can be found in the Company’s Annual Report on Form 10-K for the year ended
December 31, 2024 and the Company’s other filings with the Securities and Exchange
Commission (SEC) available at the SEC’s Internet site (www.sec.gov) .
Appendix
Generic product names are provided below.
Pharmaceutical
BRIDION (sugammadex)
CAPVAXIVE (Pneumococcal 21-valent Conjugate Vaccine)
ENFLONSIA (clesrovimab-cfor)
GARDASIL (Human Papillomavirus Quadrivalent [Types 6, 11, 16 and 18] Vaccine,
Recombinant)
GARDASIL 9 (Human Papillomavirus 9-valent Vaccine, Recombinant)
JANUMET (sitagliptin and metformin HCl)
JANUVIA (sitagliptin)
KEYTRUDA (pembrolizumab)
KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph)
LAGEVRIO (molnupiravir)
Lenvima (lenvatinib)
Lynparza (olaparib)
M-M-R II (Measles, Mumps and Rubella Virus Vaccine Live)
OHTUVAYRE (ensifentrine)
PREVYMIS (letermovir)
PROQUAD (Measles, Mumps, Rubella and Varicella Virus Vaccine Live)
Reblozyl (luspatercept-aamt)
ROTATEQ (Rotavirus Vaccine, Live, Oral, Pentavalent)
Simponi (golimumab)
VARIVAX (Varicella Virus Vaccine Live)
VAXNEUVANCE (Pneumococcal 15-valent Conjugate Vaccine)
WELIREG (belzutifan)
WINREVAIR (sotatercept-csrk)
Animal Health
BRAVECTO (fluralaner)
###

-- 15 of 16 --

- 16 -
Media Contacts: 	Investor Contacts:
Michael Levey
michael.levey@msd.com
John Cummins
john.cummins2@msd.com
Peter Dannenbaum
(732) 594-1579
Steven Graziano
(732) 594-1583

-- 16 of 16 --